Table 2.
Univariate and multivariate analyses of factors associated with tumor recurrence of hepatocellular carcinoma patients who underwent curative resection
| Characteristics | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Gender, Female vs. Male | 1.43 (0.73-2.80) | 0.292 | ||
| Age (years), < 65 vs. ≥ 65 | 0.78 (0.48-1.29) | 0.337 | ||
| Body Mass Index, (kg/m2) | 0.94 (0.59-1.50) | 0.796 | ||
| Diabetes Mellitus, Absent vs. Presence | 0.90 (0.51-1.6) | 0.715 | ||
| Hypertension, Absent vs. Presence | 0.86 (0.53-1.4) | 0.863 | ||
| Smoking, Absent vs. Presence | 1.02 (0.60-1.72) | 0.946 | ||
| AST (IU/L), < 40 vs. ≥ 40 | 2.08 (1.29-3.37) | 0.003 | 1.93 (1.18-3.17) | 0.009 |
| ALT (IU/L), < 40 vs. ≥ 40 | 1.39 (0.87-2.23) | 0.167 | ||
| Total Bilirubin (mg/dl), < 1.2 vs. ≥ 1.2 | 1.10 (0.62-1.95) | 0.740 | ||
| Albumin (g/dl), < 3.5 vs. ≥ 3.5 | 0.46 (1.7-1.27) | 0.133 | ||
| Platelet count (×103/ml), < 100K vs. ≥ 100K | 0.98 (0.36-2.68) | 0.960 | ||
| INR, < 1.0 vs. ≥ 1.0 | 1.16 (0.65-2.05) | 0.620 | ||
| AFP (ng/dl) < 200 vs. ≥ 200 | 0.95 (0.52-1.74) | 0.877 | ||
| Liver cirrhosis, Absent vs. Presence | 1.34 (0.81-2.21) | 0.250 | ||
| Child-Pugh class, A vs. B | 0.05 (0.01-131) | 0.636 | ||
| Operative margin (cm), < 1.0 vs. ≥ 1.0 | 1.39 (0.84-2.31) | 0.199 | ||
| Tumor number, Single vs. Multiple | 1.47 (0.70-3.08) | 0.306 | ||
| Tumor size (cm), < 5 vs. ≥ 5 | 1.06 (0.66-1.72) | 0.806 | ||
| Edmondson-Steiner Grade I-II vs. III-IV | ||||
| Macrovascular invasion, Absent vs. Presence | 1.12 (0.51-2.45) | 0.778 | ||
| Microvascular invasion, Absent vs. Presence | 1.05 (0.58-1.89) | 0.868 | ||
| Lymph node invasion, Absent vs. Presence | 1.69 (0.41-6.92) | 0.464 | ||
| TNM stage, I-II vs. III-IV | 1.89 (1.08-3.40) | 0.026 | 1.62 (0.92-2.87) | 0.098 |
| BCLC stage, 0-A vs. B-C | 1.72 (0.96-3.09) | 0.070 | ||
| ALDH2 rs671 genotype, GG vs. GA/AA | 2.63 (1.58-4.38) | 0.000 | 2.66 (1.59-4.43) | 0.000 |
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; AFP: Alpha-fetoprotein; BCLC stage: Barcelona clinic liver cancer.